Sort
23,748 grants matching “melanoma”
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma
$156,122Marka Crittenden · Providence Portland Medical Center · R21 · FY2014 · CA
A research and training program for junior clinicians in treating metastatic mela
$156,084Harriet M Kluger · Yale University · K24 · FY2017 · CA
A research and training program for junior clinicians in treating metastatic mela
$156,084Harriet M Kluger · Yale University · K24 · FY2016 · CA
A research and training program for junior clinicians in treating metastatic mela
$156,084Harriet M Kluger · Yale University · K24 · FY2015 · CA
A research and training program for junior clinicians in treating metastatic mela
$156,084Harriet M Kluger · Yale University · K24 · FY2014 · CA
A research and training program for junior clinicians in treating metastatic mela
$156,084Harriet M Kluger · Yale University · K24 · FY2013 · CA
Cell and Tissue Imaging Facility
$156,013Simon C Watkins · University Of Pittsburgh At Pittsburgh · P30 · FY2017 · CA
Cancer Prevention and Control Research Program
$156,000Susan A Flocke · Oregon Health & Science University · P30 · FY2025 · CA
Phase I Designs for Combined Immunotherapies in Cancer
$155,958Nolan Wages · University Of Virginia · K25 · FY2015 · CA
Phase I Designs for Combined Immunotherapies in Cancer
$155,958Nolan Wages · University Of Virginia · K25 · FY2016 · CA
Phase I Designs for Combined Immunotherapies in Cancer
$155,958Nolan Wages · University Of Virginia · K25 · FY2017 · CA
Phase I Designs for Combined Immunotherapies in Cancer
$155,958Nolan Wages · University Of Virginia · K25 · FY2018 · CA
Phase I Designs for Combined Immunotherapies in Cancer
$155,958Nolan Wages · University Of Virginia · K25 · FY2014 · CA
IMCPL / Flow Cytometry
$155,913Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P01 · FY2010 · CA
The RAC1 Pathway as aTarget for Melanoma Therapy
$155,903Joseph Schlessinger · Yale University · P50 · FY2014 · CA
Carotenoids as protectors against UVB induced cutaneous damage.
$155,893Tatiana M Oberyszyn · Ohio State University · R21 · FY2013 · CA
Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cancer
$155,875Samuel I Gunderson · Rutgers, The State Univ Of N.J. · R21 · FY2016 · CA
Molecular Diversity of Melanomas and Response to Targeted Therapy
$155,827Ruth Halaban · Yale University · P50 · FY2014 · CA
Biostatistics Core
$155,810Yan Lin · University Of Pittsburgh At Pittsburgh · P50 · FY2017 · CA
Development of Novel Markers for Melanoma Progression
$155,802Byungwoo Ryu · Nevada Cancer Institute · K01 · FY2009 · CA
The PD-1/B7-H1 Pathway and Melanoma Immunity
$155,783Lieping Chen · Yale University · P50 · FY2016 · CA
Administration and Coordination Core
$155,782Gaudenz Danuser · Ut Southwestern Medical Center · U54 · FY2024 · CA
5 ASA 2 DEOXYCYTIDINE (DAC) IN PATIENTS W/ ADVANCED MALIGNANCIES
$155,764University Of Southern California · M01 · FY2001 · RR
SEQUENTIAL CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE &IFOSFAM
$155,764University Of Southern California · M01 · FY2001 · RR
COMMUNITY CLINICAL ONCOLOGY PROGRAM
$155,732Evanston Northwestern Healthcare Res Ins · U10 · FY2001 · CA